.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CA01_Vinblastine.Vinblastine

Information

Vinblastine is a vinca alkaloid antineoplastic agent used in the treatment of various cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, breast cancer, and Kaposi's sarcoma. It works by inhibiting microtubule formation in mitotic spindle assembly, causing cell cycle arrest and apoptosis. Vinblastine is FDA-approved and widely used as part of combination chemotherapy regimens.

Pharmacokinetics

Pharmacokinetic parameters reported for adults with cancer (various cancers) after intravenous administration.

References

1. Frampton, JE, & Moen, MD (2010). Vinflunine. Drugs 70(10) 1283–1293. DOI:10.2165/11204970-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20568834

2. Nguyen, L, et al., & Variol, P (2002). Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. British journal of clinical pharmacology 53(5) 459–468. DOI:10.1046/j.1365-2125.2002.01581.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/11994051

3. Variol, P, et al., & Puozzo, C (2002). A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. European journal of clinical pharmacology 58(7) 467–476. DOI:10.1007/s00228-002-0506-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12389069

Revisions

• 06/2025 initial generated model